Literature DB >> 2807305

Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.

D K Sommers1, J Moncrieff, J Avenant.   

Abstract

1. The metabolic 4-hydroxylation of debrisoquine has been studied in a group of 98 black African villagers in Vendaland. 2. The metabolic alpha-hydroxylation of metoprolol has been studied in 94 of the same black African villagers. 3. A 4% prevalence of poor oxidative metabolism of debrisoquine and a 7.4% incidence of poor oxidation of metoprolol were found. The 4% result for debrisoquine differs considerably from the 19% found in San Bushmen, 30% in Hong Kong Chinese, 9% in Britains and 0% in Nigerians and Japanese, whilst the 7.4% result for metoprolol compares with 8.4% in Britains but differs from 0% in Nigerians and 4.1% in San Bushmen. 4. None of the poor oxidative metabolizers of debrisoquine were also poor oxidative metabolizers of metoprolol. This is contrary to results in British and Nigerian subjects where defective oxidation of metoprolol co-segrates with that of debrisoquine. 5. No similarities were found between the Venda metabolic ratio (MR) distributions and either extensive or poor MR distributions in Britains or Nigerians.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807305     DOI: 10.1177/096032718900800506

Source DB:  PubMed          Journal:  Hum Toxicol        ISSN: 0144-5952


  4 in total

1.  Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Authors:  T M Dodgen; C De J Labuschagne; A van Schalkwyk; F E Steffens; A Gaedigk; A D Cromarty; M Alessandrini; M S Pepper
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 2.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 3.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

4.  Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.

Authors:  Shehu S Awandu; Jaishree Raman; Takalani I Makhanthisa; Philip Kruger; John Frean; Teun Bousema; Jandeli Niemand; Lyn-Marie Birkholtz
Journal:  Malar J       Date:  2018-03-20       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.